Life Science Cares Boston is pleased to announce the election of John Maraganore—former founding CEO of Alnylam Pharmaceuticals — and Terry-Ann Burrell—CFO of Beam Therapeutics—to its Board of Directors.

“We are thrilled to add John and TA—two incredible well-respected industry leaders—to the LSC Boston board. They have each shown deep commitment to our mission to disrupt the cycle of poverty and inequity in our community and will bring their individual strengths to our organization as we continue to grow,” said Abe Ceesay, LSC Boston Board Chair and CEO of Rapport Therapeutics.

Dr. Maraganore brings nearly four decades of experience and connections in the industry, having served as the founding CEO and a Director of Alnylam Pharmaceuticals, Inc. from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines. He held leadership roles prior at Millennium Pharmaceuticals, Biogen, ZymoGenetics and the Upjohn Company.

Dr. Maraganore is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also a member of the Board of Directors of publicly traded companies, including Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., and Takeda Pharmaceuticals. He is also on the Board of a number of private companies, including Aerium, Hemab, Aera, Orbital, Aitia, and Versanis, and on the Board of the Biotechnology Innovation Organization, or “BIO,” where he was Chair from 2017-2019 and is Chair Emeritus.

Dr. Maraganore also serves as a strategic advisor to a number of innovative biotechnology companies, with a focus on mentoring CEOs in their mission to advance science and innovation for patients.

“Life Science Cares has an incredibly bold vision and mission to harness the good in our life sciences industry to end poverty and inequity in the communities where we grow and build our businesses,” Dr. Maraganore said. “I’m thrilled to join the LSC board and work with the broader LSC team to fulfill our important community objectives.”

Terry-Ann Burrell is Chief Financial Officer of Beam Therapeutics. Prior to Beam, Ms. Burrell spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. She was instrumental in advising clients on transaction considerations, including strategic rationale, valuation and structuring, and engaged with more than 100 companies during her tenure. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. Ms. Burrell has been a member of the Recursion Board since 2020.

“There is no industry better suited to tackle an issue as long-standing and complex as poverty. I know my colleagues to be among the most committed, creative and collaborative out there, and I am excited to help build and strengthen the formidable LSC Network of Good,” Ms. Burrell said.

The LSC Boston Board of Directors sets the strategic direction of the organization and is responsible for the nonprofit’s fiscal health. Board members help to govern and lead the organization’s collective corporate social responsibility effort as it continues to expand impact in the Greater Boston area. For more information about Life Science Cares, visit thttps://lifesciencecares.org/boston/.

Bitcore Method